BioHarvest Sciences Aktie

View in Terminal

Loading quotes...

Forecast

The analysts' average price target is €4.46 (+191.50%). The median is €4.46 (+191.50%).

Buy	3
Hold	0
Sell	0

News Go to news feed

BioHarvest Sciences reports smaller net loss and first major CDMO agreement

BioHarvest Sciences posted Q2 2026 revenue of $8.8m and a reduced net loss of $3.7m ($0.17 per share). The company announced its first major CDMO manufacturing and supply agreement in the fragrance sector, which could generate $20–30m in revenue in 2027/2028. BioHarvest lowered its full‑year revenue guidance but emphasized a strategic focus on higher‑margin CDMO projects and is targeting consolidated EBITDA breakeven for 2027; cash and equivalents rose to $16.2m. » More on de.investing.com

Financials

In the last quarter, BioHarvest Sciences Aktie had revenue of €7.74M and net profit of -€3.26M

(EUR)	June 2026	YoY
Revenue	7.74M	7.18%
Gross profit	4.45M	3.19%
Net profit	-3.26M	5.96%
EBITDA	-1.77M	47.80%

Fundamentals

Metric	Value
Market capitalization	€26.56M
Number of shares	17.33M
52-week high/low	€10.87 - €1.22
Dividends	No
Beta	1.38
P/E ratio	-3.19
PEG ratio	-0.12
P/B ratio	1.97
P/S ratio	0.84

Company profile

BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contract development and manufacturing operation services. In addition, the company offers wellness products. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red grapes. The company operates in Israel and the United States. BioHarvest Sciences Inc. is based in Vancouver, Canada.